Annual Reports for Approved Premarket Approval Applications (PMA) Guidance for Industry and Food and Drug Administration Staff December 2019

GUIDANCE DOCUMENT

• Docket Number: FDA-2006-D-0039
• Issued by: Center for Devices and Radiological Health; Center for Biologics Evaluation and Research

Devices subject to premarket approval under section 515 of the Federal Food, Drug, and Cosmetic Act (the Act) are subject to periodic reporting requirements set forth in the PMA approval order (21 CFR 814.82(a), 21 CFR 814.84(b)). This guidance document describes the information required to be submitted in annual reports under 21 CFR 814.84(b), additional information requirements that may be imposed by approval order under 21 CFR 814.82(a), and FDA’s recommendations for the level of detail the applicant should provide in the annual report. It also identifies the steps FDA staff generally take when reviewing annual reports, the resources available to assist staff in their reviews, and the actions they may recommend after reviewing annual reports. This guidance document is intended to help ensure that annual reports are complete and that the actions of CDRH and CBER staff are consistent.

FDA’s guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word “should” in Agency guidances means that something is suggested or recommended, but not required.

---

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2006-D-0039.